Anuh Pharma's Q1 2024 Financial Results Show Mixed Performance, Investors Advised to Hold Stock

Anuh Pharma, a smallcap pharmaceutical company, recently announced its financial results for the quarter ending June 2024. The company's stock has been given a 'Hold' call by MarketsMOJO. According to the financials, Anuh Pharma has seen a negative performance in the quarter, with a score of -11 compared to 8 in the previous quarter. However, there are some positive aspects to the company's performance. Anuh Pharma has consistently shown growth in its dividend per share (DPS) over the last five years, with the highest DPS of Rs 2.50. This indicates that the company is distributing higher dividends from its profits. On the other hand, there are some areas of concern for Anuh Pharma. The profit before tax (PBT) has fallen by 48.3% compared to the average of the previous four quarters. The profit after tax (PAT) has also seen a decline of 36.7% compared to the average of the previous four quarters. The net sales have also fallen by 14.7% compared to the average of the previous four quarters. The company's operating cash flow has also decreased, with the lowest amount in the last three years. In addition, the operating profit (PBDIT) and operating profit margin have also seen a decline in the last five quarters. The earnings per share (EPS) and dividend payout ratio (DPR) have also decreased, indicating a decline in profitability and lower distribution of profits as dividends. The company's non-operating income has increased, but it may not be sustainable in the long run. Overall, Anuh Pharma's financial performance for the quarter ending June 2024 has been negative, with some positive and negative aspects. Investors are advised to hold their stock and monitor the company's performance in the upcoming quarters.